Leap Therapeutics logo
Leap Therapeutics LPTX

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Leap Therapeutics Income Statement 2011-2026 | LPTX

Annual Income Statement Leap Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

43.8 M 3.51 M 278 M 178 M 42.2 M 30.8 M 64.4 M 68.6 M - - - - -

Shares

20.4 M 11.3 M 85.8 M 76.3 M 22.6 M 14.1 M 9.16 M 9.39 M - - - - -

Historical Prices

2.14 0.31 3.24 2.25 1.12 2 6.24 - - - - - -

Net Income

-81.4 M -54.6 M -40.6 M -27.5 M -32.9 M -23.1 M -29.7 M -25.6 M -21.1 M -25.5 M -18.3 M -7.76 M -

Revenue

- - 1.5 M 1.5 M - - - - - - - - -

Gross Profit

- - - 1.5 M - - - - - - - - -

Operating Income

-87 M -56.8 M -41.4 M -28.5 M -33.5 M -30.8 M -32.4 M -27.3 M - - - - -

Interest Expense

- 54 K 41 K 39 K 23 K 19 K 528 K -9 K - - - - -

EBITDA

-87 M -56.7 M -41.4 M -28.3 M -33.3 M -29.9 M -32.3 M -24.4 M -20.5 M -19.7 M -13.2 M -6.98 M -

Operating Expenses

87 M 56.8 M 42.9 M 29.8 M 33.3 M 30 M 32.4 M - - - - - -

General and Administrative Expenses

13.8 M 11.8 M 10.8 M 9.62 M 9.08 M 8.92 M 9.85 M 4.23 M 5.72 M 4.71 M 4.57 M 1.51 M -

All numbers in USD currency

Quarterly Income Statement Leap Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

41.4 M 41.4 M 41.3 M 38.3 M 41.2 M 39.1 M 27 M 25.6 M 27 M 14.7 M 12.9 M 9.9 M 11.3 M 11.3 M 113 M 88.3 M 78.2 M 76.4 M 76.4 M 59.7 M 76.3 M 52.4 M 31.6 M 24.2 M 23.9 M 22.9 M 19.2 M 14.7 M 14.7 M 14.7 M 12.4 M 12.4 M 9.4 M 9.39 M 6.95 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-3.3 M -16.6 M -15.4 M - -18.2 M -20.1 M -13.8 M - -13.7 M -13.4 M -41.9 M - -15.1 M -17 M -10.4 M - -11.1 M -9.53 M -9.13 M - -7.06 M -6.52 M -7.23 M - -7.94 M -8.37 M -8.6 M - -6.63 M -7.36 M -10.6 M - -6.82 M -6.9 M -9.41 M - -7.28 M -7.48 M -5.15 M - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - 375 K 375 K 375 K - 375 K 375 K 375 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.17 M -16.9 M -15.9 M - -17.9 M -21.3 M -14.8 M - -14.8 M -14.7 M -42.7 M - -15.3 M -16.9 M -10.6 M - -12.1 M -9.63 M -9.17 M - -7.51 M -7.5 M -6.38 M - -7.92 M -8.46 M -8.8 M - -8.6 M -6.84 M -6.34 M - -8.58 M -7.02 M -10.2 M - -7.03 M -7.19 M -5.14 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - - 11 K 17 K 21 K - 9 K 16 K 14 K - 17 K 13 K 12 K - 5 K 9 K 7 K - 4 K 8 K 6 K - 21 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - -14.8 M - - - -42.7 M - -15.3 M -16.9 M -10.6 M - -12.1 M -9.61 M -9.16 M - -7.48 M -7.48 M -6.37 M - -7.89 M -8.44 M -8.78 M - -8.56 M -6.81 M -6.33 M - -8.55 M -6.99 M -10.2 M - -7.01 M -7.19 M -5.14 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

3.17 M 16.9 M 15.9 M - 17.9 M 21.3 M 14.8 M - 14.8 M 14.7 M 42.7 M - 15.3 M 16.9 M 10.6 M - 12.5 M 10 M 9.55 M - 7.88 M 7.87 M 6.76 M - 7.92 M 8.46 M 8.8 M - 8.6 M 6.84 M 6.34 M - 8.58 M 7.02 M 10.2 M - 7.03 M 7.19 M 5.14 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.92 M 1.82 M 3.01 M - 2.94 M 3.37 M 3.53 M - 3.33 M 3.56 M 3.78 M - 3.19 M 2.86 M 2.85 M - 2.44 M 2.8 M 2.74 M - 2.51 M 2.52 M 2.15 M - 2.15 M 2.32 M 2 M - 2.14 M 2.6 M 2.11 M - 1.78 M 2.14 M 3.8 M - 1.37 M 1.07 M 1.06 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Leap Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
argenx SE argenx SE
ARGX
$ 834.06 0.94 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 234.24 -0.3 % $ 5 B danmarkDanmark
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.81 1.31 % $ 4.42 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.66 1.42 % $ 393 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 167.61 -4.09 % $ 8.34 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.33 0.79 % $ 8.01 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioVie BioVie
BIVI
$ 1.25 0.4 % $ 1.85 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 63.02 0.15 % $ 12 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 0.79 4.29 % $ 108 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.71 10.81 % $ 837 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 27.89 0.07 % $ 747 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.88 0.86 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.72 2.08 % $ 4.55 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Certara Certara
CERT
$ 6.67 2.77 % $ 1.07 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.32 1.25 % $ 1.5 B britainBritain
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.85 6.65 % $ 472 M britainBritain